Yan-Qin Geng, Li-Na Qiu, Yuan-Qiu Cheng, Juan-Juan Li, Yi-Lin Ma, Cheng-Cheng Zhao, Ying Cai, Xue-Bin Zhang, Jieli Chen, Yu-Chen Pan, Ke-Rang Wang, Xiu-Hua Yao, Dong-Sheng Guo, Jia-Ling Wu
Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) is the primary treatment for ischemic stroke. However, rtPA treatment can substantially increase blood-brain barrier (BBB) permeability and susceptibility to hemorrhagic transformation. Herein, the mechanism underlying the side effects of rtPA treatment is investigated and demonstrated that ferroptosis plays an important role. The ferroptosis inhibitor, liproxstatin-1 (Lip) is proposed to alleviate the side effects. A well-designed macrocyclic carrier, glucose-modified azocalix[4]arene (GluAC4A), is prepared to deliver Lip to the ischemic site...
April 22, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)